Gigantic Biotech Trade Highlights Insider Buying: Seattle Genetics, Bank of New York Mellon, Prospect Capital and More
Maybe, just maybe, investors are starting to see the light at the end of the tunnel, and it’s not the selling train that has run shareholders over since the start of 2016.